swissdamed: which diagnostic comes first?

A manufacturer opens its portfolio: one analyser, three reagent families, several pack sizes, legacy references and multiple identifiers. Commercially, they all belong to one range. In swissdamed, however, there is no assurance that one record will cover them. The question is no longer whether the IvDO exists, but which diagnostic to register, with which data and under whose responsibility. Device registration in swissdamed became mandatory in Switzerland on 1 July 2026, with a transition until 31 December 2026 for products already on the market. This reading starts with that current deadline and works back to the IvDO, which entered into force in 2022. It distinguishes devices, classes, transitions, UDI and economic-operator roles. It also shows how portfolio preparation can become a paid initial assignment and a focused B2B acquisition angle. The aim is practical: make the next decision visible before the team discovers a missing data point too late. General analysis based on official sources available on 6 August 2026. It is not a regulatory classification, conformity assessment, clinical decision or Swissmedic decision.

From 26 May 2022, the IvDO established a dedicated Swiss regime for in vitro diagnostic medical devices. It strengthened risk-based classification, surveillance and traceability while providing conditional transitions for selected legacy devices.

Before 2022, IVDs followed the Swiss framework derived from European Directive 98/79/EC. The new ordinance, adopted on 4 May 2022, accompanied the European IVD regulation. Because the Switzerland–EU mutual recognition agreement was not updated, Switzerland introduced its own operator and representation measures.

That history still matters in 2026. A device may follow the new regime, remain in transition or have lost that route. A certificate date alone settles nothing: class, status, intended purpose, design changes, quality system and designated-body steps must be considered together.

Keep two files distinct. The IvDO governs products and operators; swissdamed holds actor and device data. Registration proves neither conformity, analytical performance nor clinical utility, and a technical file does not remove a registration duty.

An in vitro diagnostic medical device is a product intended to examine specimens from the human body and provide information specified by its manufacturer. Within a commercial portfolio, an analyser, reagent, calibrator, control and accessory are not automatically the same device.

The word “test” can hide several regulatory objects. A range may include a platform, reagents, controls, software and packaging. Each has an intended purpose, manufacturer, status, identifiers and documentation that must agree. One catalogue line is not necessarily one registration unit.

How to read the table. Preparation starts with product identity and responsibility. A commercial inventory never becomes a regulatory decision by default.

Risk class provides an initial priority. The IvDO uses classes A, B, C and D according to intended purpose and risk, with D the highest. Acquisition teams must not infer the class. It comes from the manufacturer and the validated file. Preparation collects that decision, flags inconsistencies and assigns review to the competent person.

Class changes the length of selected conformity transitions but does not postpone Swiss device registration in swissdamed. In 2026, teams must track two timetables: how long a legacy IVD may remain on the market and when its Swiss registration is due.

Extended transitions may run to the end of 2027 for selected class D devices, 2028 for selected class C devices, and 2029 for selected class B or sterile class A devices. These are conditional routes, not general permissions. Conditions include continued compliance with the former framework, no significant design or intended-purpose change, no unacceptable risk, and the required quality management system.

Applications to a designated body also have class-specific milestones: 26 May 2025 for class D, 26 May 2026 for class C, and 26 May 2027 for class B and sterile class A. Written agreements must follow by the prescribed dates. Looking only at the final transition year can hide an intermediate step that has already passed.

Meanwhile, Swiss registration in the UDI Devices module has been mandatory since 1 July 2026, with the transition for existing devices ending on 31 December 2026. An IVD that may remain on the market until 2028 or 2029 is not exempt from swissdamed registration in 2026.

How to read the timeline. The swissdamed dates concern Swiss registration. The 2027–2029 dates concern selected conformity transitions. Both must be checked for every device.

Text alternative. The IvDO took effect in 2022. Selected transition conditions fall between 2025 and 2027, while swissdamed registration became mandatory in July 2026 and its transition ends in December 2026.

The Swiss swissdamed timetable and the European EUDAMED timetable are separate. The relevant EU modules became mandatory on 28 May 2026 with their own transition, while Swiss registration began on 1 July 2026 and its general transition ends on 31 December 2026.

Similar names create real risk. EUDAMED is the EU system; swissdamed is Swiss. Swissmedic states that the European modules declared functional became mandatory on 28 May 2026, with a transition until 27 November 2026. Those dates do not replace the Swiss deadlines.

For businesses active in both markets, the tracking table needs separate Swiss and EU columns. The same identifier may appear in both, but platform, responsible party, status and filing evidence remain market-specific. An offer covering both markets must state whether it handles Switzerland, the EU, or coordinated work with named owners.

swissdamed preparation connects the responsible actor, device, Basic UDI-DI, UDI-DI, packaging, intended purpose, class and market status. The exact dataset depends on the product and role and must be checked against the current UDI Devices guidance.

UDI is an identification system, not a stock number. Basic UDI-DI links a regulatory device family and selected documents; UDI-DI identifies a model; Package UDI-DI identifies relevant packaging levels. Legacy devices may use identifiers appropriate to their status. Labels, files, catalogue and database must agree before filing.

The commercial register supplies active references. The manufacturer or Swiss authorised representative confirms status, class and identifiers. Quality documentation supports the values. An authorised person reviews the batch, and receipts and corrections remain linked to each device.

How to read the matrix. A catalogue reference progresses only when its status, identifiers, evidence and decision owner align.

The relevant manufacturer, authorised representative or system and procedure pack producer registers the device according to its role and the applicable rules. A provider may prepare data and a filing batch, but regulatory classification, declared accuracy and surveillance remain with the competent operators.

Swissmedic separates actor registration from device registration. Swiss economic-operator registration has been mandatory since 26 November 2021; the swissdamed Actors module has been available since August 2024. The UDI Devices module then holds product data. A registered actor has not automatically registered its portfolio.

How to read the diagram. The commercial team opens the inventory, regulatory affairs qualifies it, the authorised operator registers, and quality maintains the evidence. No step transfers a medical responsibility to getfishnet.

Registration becomes immediately urgent when a device is linked to a serious incident, field safety corrective action or trend report. Swissmedic requires these cases to be registered without waiting for the transition to end, so vigilance can be connected to the device.

This creates a better order than alphabetical processing: vigilance cases first, then active products with high operational importance, incomplete data, and references already marked for discontinuation. The regulatory owner must approve the order.

In-house IVDs used within health institutions follow another route. Swissmedic phased their reporting duty by class and will end grouped declarations from 1 January 2027, when each in-house IVD must be declared individually. That workload may matter to laboratories but is distinct from a manufacturer or representative's commercial portfolio.

A paid initial assignment can be a swissdamed readiness diagnostic for a defined portfolio: active references, roles, validated classes, identifiers, missing evidence, priorities and filing-ready batches. It organises information; it does not issue a certificate, medical classification or market-access guarantee.

The client supplies a reference export, Swiss entity roles, existing identifiers and internal owners. The partner checks completeness, records gaps and prepares a decision list. “Ready” means the agreed data checks are complete, not that Swissmedic has approved the product.

The scope is observable: a set number of references or one regulatory family, a status register, and either a filing batch or assigned gaps. Partner pricing, timing, capacity, professional insurance and contractual liability must be confirmed before a campaign. Device counts cannot establish market value: a device is not a client. Portfolio size helps estimate work only after qualification.

The diagnostic should also assign every gap to an owner and a deadline. Without those two fields, the inventory remains descriptive and cannot support a purchasing decision. With them, the partner can price the first batch, reserve qualified capacity and state which records remain outside scope. A buyer then sees a finite operational result rather than an open-ended compliance project, while the regulatory team keeps control of classification, evidence and submission.

Priority accounts are manufacturers and authorised representatives with devices already sold in Switzerland, an identifiable portfolio and a documented gap before the end of 2026. Targeting must confirm a decision-maker, workload and partner capacity; a “medtech” label is not enough.

Useful signals include an active Swiss catalogue, recent representative change, regulatory hiring, range expansion, inherited products, a vigilance event or scattered UDI data. The opening question is operational: how many active references must be matched to a role, status and identifier before the deadline?

The opportunity receives a conditional GO for portfolio preparation tied to the current deadline. It is a STOP for a generic campaign to every medtech company, any promise of market access, or a provider unable to own the review. Scaling remains on hold until competence, pricing, workload and one genuinely paid transaction are validated.

Credible B2B acquisition starts with portfolio signals and roles, then chooses channels that reach the responsible people. It sells a bounded decision and verifiable output; it never turns a public deadline or device database into an automatic client list.

Account research can combine manufacturers, representatives, distributors, product announcements, hiring and Swiss activity. Content explains transitions, registration, UDI structure and missing data. Search captures explicit intent; professional networks, phone, email, voice messages and referrers open a conversation where the signal is specific enough.

How to read the funnel. Purchase requires a portfolio, responsibility, a gap and an offer the partner can deliver. Market size alone does not enter the funnel.

Continue when qualified accounts buy a profitable batch and the partner delivers on time. Refine targeting when portfolios fall outside scope, refine the offer when need does not convert into a purchase, and stop when responsibility or capacity cannot be secured.

Measure confirmed Swiss activity, responsible contacts, portfolios that can be priced, accepted proposals, cash collected, expert hours and gaps resolved. Full acquisition cost includes data, tools, media, production, commercial time and regulatory time, and is compared with margin rather than revenue alone.

An initial batch can lead to ongoing work when a range addition, new identifier, operator change, data correction or vigilance event triggers another defined task. Recurring revenue must reflect real maintenance, never a subscription without responsibility or output.

A useful portfolio register retains the date, owner, evidence and next review. Every event creates a work order, deadline and audit trail. Continuity also requires stable governance: a regulatory lead, quality control, access management, evidence retention, escalation and reserved capacity. Monthly revenue, retention and margin can be stated only after a real relationship documents them.

The reading on MedDO and the Switzerland–EU MRA covers medical devices other than IVDs. The Medtech archive compares validated readings without mixing their regimes.

The current obligations can be checked in the consolidated IvDO on Fedlex, Swissmedic guidance on swissdamed, UDI and operators, and the European Commission's published IVD transition provisions.

The core sources are Fedlex's Ordinance on In Vitro Diagnostic Medical Devices; Swissmedic's guidance on device registration in swissdamed, registration duties, UDI, Swiss economic operators and individual declarations for in-house IVDs; and the European Commission's transition provisions for IVDs. This article names them without public external links. They must be checked again at execution because analysis never replaces the consolidated law, current module guide or competent advice.

The swissdamed deadline supports a credible initial IVD portfolio assignment, not a general promise of compliance. The market becomes actionable only when the partner can evidence competence, capacity, pricing, margin and the precise responsibility it accepts.

The opportunity is to remove a concrete uncertainty: which references exist, which are active, who owns them, what data is missing and which batch can be filed. getfishnet can build tailored account research, signals, messages, channels, qualification and an initial offer around that process, while keeping commercial validation separate from regulatory responsibility.